Age is an independent adverse prognostic factor for overall survival in acute myeloid leukemia in Japan

Figure 1 Kaplan-Meier estimate of overall survival in patients with non-acute promyelocytic leukemia. A: All patients; B: Patients categorised by age group. Black line, ≤ 64 years; dotted line, 65-74 years; grey line, ≥75 years; C: Patients categorised by performance status (PS). Black line, PS 0-2; dotted line, PS 3-4; D: Patients categorised by intensity of induction chemotherapy. Black line, intensive chemotherapy; dotted line, less intensive chemotherapy; grey line, best supportive care; E: Patients categorised by antecedent hematological disease. Black line, without antecedent hematological disease; dotted line, with antecedent haematological disease; F: Patients categorised according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines karyotype classification. Black line, favourable and intermediate risk karyotypes; dotted line, unfavourable risk karyotypes; G: Patients categorised according to the Southwest Oncology Group (SWOG) karyotype classification. Black line, favourable and intermediate risk karyotypes; dotted line, unfavourable risk karyotypes; H: Patients categorised according to the Cancer and Leukemia Group B (CALGB) karyotype classification. Black line, favourable and intermediate risk karyotypes; dotted line, unfavourable risk karyotypes.

Figure 2 Early death rate and complete remission rate according to performance status in different age groups. A: Proportions of patients with good and poor performance status (PS) in different age groups. Grey, PS 0-2; black, PS 3-4; B: Early death rate according to PS in different age groups. Black line, PS 0-2; dotted line, PS 3-4; C: Complete remission rate according to PS in different age groups. Black line, PS 0-2; dotted line, PS 3-4.